Daiichi Sankyo’s One-Dose Version Of GSK’s Relenza Rivals Tamiflu
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo's one-dose version of GlaxoSmithKline's Relenza (zanamivir) flu drug has shown in trials to be just as effective as the two-dose regimen for Roche Holding's Tamiflu (oseltamivir), according to a study. Daiichi Sankyo plans to begin Phase III studies for its drug in several countries this coming winter. The usual regimen for the two major flu drugs has been twice a day for five days. Daiichi has given its drug the temporary name of CS-8958, in the same class as the other two drugs for preventing the spread of flu viruses beyond the infected cell. (Click here for more
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.